Waddell & Reed Financial’s Seres Therapeutics MCRB Stock Holding History

Waddell & Reed Financial’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-17,705	Closed	-$4.35M	–	604
2016 Q3	$4.35M	Sell	17,705 -19,031	-52%	-$6.68M	0.01%	528
2016 Q2	$21.3M	Buy	36,736 +7,458	+25%	+$4.38M	0.05%	298
2016 Q1	$15.6M	Hold	29,278	–	–	0.03%	336
2015 Q4	$20.5M	Buy	29,278 +5,060	+21%	+$3.33M	0.03%	309
2015 Q3	$14.4M	Buy	24,218 +9,153	+61%	+$7.47M	0.02%	357
2015 Q2	$12.5M	Buy	+15,065	New	+$13.1M	0.02%	404

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Waddell & Reed Financial's MCRB Position: Q4 2016 in Review

Waddell & Reed Financial sold out of Seres Therapeutics (MCRB) in Q4 2016, closing a stake of 17,705 shares — an estimated $4.35M sold.

Waddell & Reed Financial first reported a position in MCRB in Q2 2015 and held it in 6 quarters. The position peaked at $21.3M in Q2 2016. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

Waddell & Reed Financial reported no remaining Seres Therapeutics position as of Q4 2016 after selling out during the quarter.
Waddell & Reed Financial sold 17,705 Seres Therapeutics shares in Q4 2016, an estimated $4.35M.
Waddell & Reed Financial first reported a position in Seres Therapeutics in Q2 2015 and held it in 6 quarters.
Waddell & Reed Financial's Seres Therapeutics position peaked at $21.3M in Q2 2016.
89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on Waddell & Reed Financial's 13F filing for Q4 2016, filed 14 Feb 2017.